Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age‐related macular degeneration: a comparative 12 Month study
Authors:
- 24 March 2016
- journal article
- research article
- Published by Wiley in Acta Ophthalmologica
- Vol. 95 (1) , E67-E72
Abstract
Purpose: To compare outcomes in patients with treatment‐naïve neovascular age‐related macular degeneration (nAMD) receiving ranibizumab treat and extend (TE) with those receiving ranibizumab pro re nata (PRN) in a clinical setting.Methods: During this 12‐month retrospective, consecutive, comparative case series, patients received ranibizumab 0.5 mg according to a TE or PRN regimen. Monthly optical coherence tomography (OCT) evaluation was performed during the PRN regimen; retreatment criteria included recurrence of intra‐/subretinal fluid, or haemorrhages. During the TE regimen, initial treatment with 4‐week intervals was sequentially lengthened by 2 weeks until signs of choroidal neovascularization (CNV) activity recurred. Study end‐points included mean change in best corrected visual acuity (BCVA) and central retinal thickness (CRT), mean injection frequency and number of follow‐up visits attended.Results: Baseline characteristics were similar between the TE (n = 70) and PRN (n = 70) groups. Mean change in BCVA from baseline to Month 12 was significantly greater in the TE group than the PRN group (+0.18 ± 0.17 versus +0.07 ± 0.20, p < 0.001). Mean change in CRT from baseline to Month 12 was greater in the TE group than the PRN group (−116 ± 132 versus −58 ± 157 μm, p = 0.019). The number of follow‐up visits attended was significantly higher in the PRN group than the TE group (11.9 ± 1.1 versus 8.6 ± 1.9, p < 0.001), while patients in the TE group received more injections during the study than those in the PRN group (8.6 ± 1.9 versus 6.0 ± 1.9, p < 0.001).Conclusion: Ranibizumab administered using a TE regimen in treatment‐naïve patients with nAMD provided better visual outcomes with fewer clinic visits, compared with a PRN regimen.Keywords
Funding Information
- Novartis Pharma
This publication has 31 references indexed in Scilit:
- Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE StudyOphthalmology, 2011
- INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDEDRetina, 2011
- A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular DegenerationOphthalmology, 2010
- LONG-TERM FOLLOW-UP FOR TYPE 1 (SUBRETINAL PIGMENT EPITHELIUM) NEOVASCULARIZATION USING A MODIFIED “TREAT AND EXTEND” DOSING REGIMEN OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPYRetina, 2010
- “TREAT AND EXTEND” DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATIONRetina, 2009
- Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trialsBritish Journal of Ophthalmology, 2009
- The Natural History and Prognosis of Neovascular Age-Related Macular DegenerationOphthalmology, 2008
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularizationActa Ophthalmologica Scandinavica, 2006